EcoDrugPlus

Tubulin Alpha 4a

Ensembl ID : ENSPEMG00000029240
Gene Symbol: TUBA4A
3 Cross references
224 Possible Orthologues:

Tubulin Alpha-1c Chain

Ensembl ID : ENSPEMG00000025359
Gene Symbol: LOC102916382
3 Cross references
119 Possible Orthologues:

Tubulin Alpha-3 Chain

Ensembl ID : ENSPEMG00000028173
Gene Symbol: LOC102907987
2 Cross references
203 Possible Orthologues:

Tubulin Alpha-3 Chain

Ensembl ID : ENSPEMG00000025965
Gene Symbol: LOC102907987
2 Cross references
203 Possible Orthologues:

Tubulin Beta 3 Class Iii

Ensembl ID : ENSPEMG00000019163
Gene Symbol: TUBB3
3 Cross references
144 Possible Orthologues:

Tubulin Beta 4a Class Iva

Ensembl ID : ENSPEMG00000028633
Gene Symbol: TUBB4A
3 Cross references
94 Possible Orthologues:

Tubulin Beta 4b Class Ivb

Ensembl ID : ENSPEMG00000030881
Gene Symbol: TUBB4B
3 Cross references
316 Possible Orthologues:

Tubulin Beta 6 Class V

Ensembl ID : ENSPEMG00000011359
Gene Symbol: TUBB6
3 Cross references
141 Possible Orthologues:

Tubulin Beta Class I

Ensembl ID : ENSPEMG00000025556
Gene Symbol: TUBB
3 Cross references
291 Possible Orthologues:

Tubulin Beta-2b Chain

Ensembl ID : ENSPEMG00000008538
Gene Symbol: LOC102919406
3 Cross references
181 Possible Orthologues:

Tubulin, Beta 1 Class Vi

Ensembl ID : ENSPEMG00000025434
Gene Symbol: TUBB1
1 Cross references
186 Possible Orthologues:

Type-1a Angiotensin Ii Receptor

Ensembl ID : ENSPEMG00000029887
Gene Symbol: LOC102915006
3 Cross references
195 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).